المؤلفون: Bando, Hiroshi

مصطلحات موضوعية: Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD) study, Canagliflozin cardioVascular Assessment Study (CANVAS), Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) study, The Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients-Removing Excess Glucose (EMPA-REG OUTCOME) study, sodium–glucose cotransporter 2 (SGLT2) inhibitors

Relation: http://repo.lib.tokushima-u.ac.jp/files/public/11/115290/20200924104704324348/emij_8_4_97.pdf; http://repo.lib.tokushima-u.ac.jp/115290

الاتاحة: http://repo.lib.tokushima-u.ac.jp/115290

المؤلفون: Rishad Ahmed, Pallavi Kawatra

المصدر: BLDE University Journal of Health Sciences, Vol 2, Iss 2, Pp 75-79 (2017)

مصطلحات موضوعية: Canagliflozin Cardiovascular Assessment Study, EMPA-REG, sodium–glucose cotransporter inhibitors, Therapeutics. Pharmacology, RM1-950

وصف الملف: electronic resource

Relation: http://www.bldeujournalhs.in/article.asp?issn=2468-838X;year=2017;volume=2;issue=2;spage=75;epage=79;aulast=Ahmed; https://doaj.org/toc/2468-838X; https://doaj.org/toc/2456-1975

URL الوصول: https://doaj.org/article/8f21a9852a15485caef3429dc5c93992

المؤلفون: Neal, B, Perkovic, V, Mahaffey, KW, Fulcher, G, Erondu, N, Desai, M, Shaw, W, Law, G, Walton, MK, Rosenthal, N, Zeeuw, D, Matthews, DR, CANVAS program collaborative group

المصدر: 935 ; 926

مصطلحات موضوعية: Science & Technology, Life Sciences & Biomedicine, Endocrinology & Metabolism, cardiovascular disease, SGLT2 inhibitor, type 2 diabetes, CANAGLIFLOZIN CARDIOVASCULAR ASSESSMENT, BASE-LINE CHARACTERISTICS, PLACEBO-CONTROLLED TRIAL, SAFETY, CONJUNCTION, RATIONALE, EFFICACY, EVENTS, DESIGN, CANVAS Program collaborative group, 1103 Clinical Sciences

Relation: Diabetes Obesity & Metabolism; http://hdl.handle.net/10044/1/44986; https://dx.doi.org/10.1111/dom.12924

الاتاحة: http://hdl.handle.net/10044/1/44986
https://doi.org/10.1111/dom.12924

المؤلفون: Hiroshi Bando

المصدر: Endocrinology & Metabolism International Journal. 8(4):97-99

مصطلحات موضوعية: Canagliflozin, medicine.medical_specialty, sodium–glucose cotransporter 2 (SGLT2) inhibitors, Adrenal disorder, business.industry, Type 2 Diabetes Mellitus, medicine.disease, Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD) study, chemistry.chemical_compound, chemistry, Canagliflozin cardioVascular Assessment Study (CANVAS), Diabetes mellitus, Internal medicine, Heart failure, medicine, Empagliflozin, Cardiology, Glucose homeostasis, Dapagliflozin, The Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients-Removing Excess Glucose (EMPA-REG OUTCOME) study, business, medicine.drug, Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) study

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cdd3e9802bea39d44adefcc322110451
http://repo.lib.tokushima-u.ac.jp/115290

المؤلفون: Dick de Zeeuw, Kent Y Feng, Greg Fulcher, Meg Jardine, David R. Matthews, Juliana Ianus, Michael Pfeifer, Kenneth W. Mahaffey, Vlado Perkovic, Bruce Neal, Jingwei Li

مصطلحات موضوعية: medicine.medical_specialty, CANAGLIFLOZIN CARDIOVASCULAR ASSESSMENT, Endocrinology, Diabetes and Metabolism, MedDRA, RATIONALE, Type 2 diabetes, Rate ratio, Placebo, Cardiovascular System, DISEASE, Endocrinology & Metabolism, Endocrinology, DESIGN, Secondary analysis, Internal medicine, BASE-LINE CHARACTERISTICS, Internal Medicine, Medicine, Humans, Hypoglycemic Agents, Canagliflozin, Sodium-Glucose Transporter 2 Inhibitors, RISK, Science & Technology, business.industry, MORTALITY, EMPAGLIFLOZIN, Type 2 Diabetes Mellitus, SGLT2 inhibitor, 1103 Clinical Sciences, medicine.disease, Confidence interval, cardiovascular outcomes, Hospitalization, Diabetes Mellitus, Type 2, type 2 diabetes, business, Life Sciences & Biomedicine, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b9acd312a343c726758cc599b11b12f
http://hdl.handle.net/10044/1/94091

المؤلفون: Feng, KY, Li, J, Ianus, J, De Zeeuw, D, Fulcher, GR, Pfeifer, M, Matthews, DR, Jardine, MJ, Perkovic, V, Neal, B, Mahaffey, KW

المصدر: 2715 ; 2707

مصطلحات موضوعية: Science & Technology, Life Sciences & Biomedicine, Endocrinology & Metabolism, canagliflozin, cardiovascular outcomes, hospitalization, SGLT2 inhibitor, type 2 diabetes, CANAGLIFLOZIN CARDIOVASCULAR ASSESSMENT, BASE-LINE CHARACTERISTICS, RISK, EMPAGLIFLOZIN, RATIONALE, MORTALITY, DISEASE, DESIGN, Cardiovascular System, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Sodium-Glucose Transporter 2 Inhibitors

Relation: Diabetes, Obesity and Metabolism: a journal of pharmacology and therapeutics; http://hdl.handle.net/10044/1/94091

الاتاحة: http://hdl.handle.net/10044/1/94091
https://doi.org/10.1111/dom.14525

المؤلفون: Pallavi Kawatra, Rishad Ahmed

المصدر: BLDE University Journal of Health Sciences, Vol 2, Iss 2, Pp 75-79 (2017)

مصطلحات موضوعية: Canagliflozin, medicine.medical_specialty, sodium–glucose cotransporter inhibitors, business.industry, Canagliflozin Cardiovascular Assessment Study, EMPA-REG, lcsh:RM1-950, General Medicine, Class effect, Sodium-Glucose Cotransporter Inhibitors, Outcome (game theory), Food and drug administration, lcsh:Therapeutics. Pharmacology, medicine, business, Intensive care medicine, Probable mechanism, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b988ea0030e5a327aac4d53cfdb67998
http://www.bldeujournalhs.in/article.asp?issn=2468-838X;year=2017;volume=2;issue=2;spage=75;epage=79;aulast=Ahmed

المؤلفون: Greg Fulcher, Wayne Shaw, Dick de Zeeuw, Gordon Law, Norm Rosenthal, Vlado Perkovic, David R. Matthews, Bruce Neal, Mehul Desai, Ngozi Erondu, Marc K. Walton, Kenneth W. Mahaffey

المساهمون: Groningen Kidney Center (GKC)

المصدر: Diabetes obesity & metabolism, 19(7), 926-935. Wiley
Diabetes, Obesity & Metabolism

مصطلحات موضوعية: Male, Process management, CONJUNCTION, Diabetic Cardiomyopathies, Endocrinology, Diabetes and Metabolism, RATIONALE, Plan (drawing), 030204 cardiovascular system & hematology, PLACEBO-CONTROLLED TRIAL, Cohort Studies, 0302 clinical medicine, Endocrinology, DESIGN, Risk Factors, cardiovascular disease, Medicine, Clinical Trial Design, CANVAS Program collaborative group, Canagliflozin, Class (computer programming), SGLT2 inhibitor, Middle Aged, Cardiovascular Diseases, SAFETY, Female, type 2 diabetes, Drug Monitoring, Life Sciences & Biomedicine, medicine.drug, CANAGLIFLOZIN CARDIOVASCULAR ASSESSMENT, Steering committee, 030209 endocrinology & metabolism, Equivalence Trials as Topic, Patient care, Food and drug administration, EVENTS, Endocrinology & Metabolism, 03 medical and health sciences, Double-Blind Method, Sodium-Glucose Transporter 2, BASE-LINE CHARACTERISTICS, Internal Medicine, Humans, Hypoglycemic Agents, Mortality, Sodium-Glucose Transporter 2 Inhibitors, Aged, Science & Technology, Dose-Response Relationship, Drug, business.industry, Reproducibility of Results, 1103 Clinical Sciences, EFFICACY, Diabetes Mellitus, Type 2, business, Biomarkers, Diabetic Angiopathies, Follow-Up Studies

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78fd7f460b50428bf602fb58a9f34afa
https://research.rug.nl/en/publications/46f1e9ef-2099-4eeb-ab60-66ff27b21848